Introduction Epidemiological studies focused on prognostic factors associated with laryngeal cancer in the Brazilian population are poorly reported in the literature. Objective To evaluate the influence of certain risk factors on the survival rates of patients with squamous cell carcinoma (SCC) of the larynx. Methods This retrospective study was conducted on adult patients who were admitted to the outpatient clinic of the head and neck department in a tertiary care hospital. Evaluation of the influence of risk factors on the survival rates of patients registered in the hospital with laryngeal SCC was performed based on age, sex, initial stage, time of evolution, habits, educational levels and relapse and death. Overall survival (OS), disease-free survival (DFS) and clinical-demographic data were analyzed using the Kaplan-Meier method, Log-rank test and Cox regression. Results A total of 107 patients with a mean age of 59.8 years (range 19–81) were included in this study. Stages III and IV were associated with decreased DFS (p = 0.02) and OS (p = 0.02). Smoking patients had a greater period of disease evolution than non-smoking patients (p = 0.003). Alcohol consumption in smokers increased the risk of death by 2.8 (p = 0.002) compared with non-drinking smokers. Male patients presented lower DFS average when compared with female patients (p = 0.04). Conclusion Our study confirms that male gender, smoking habit combined with alcohol consumption, and advanced stages were strongly associated with poor prognosis.

Background Recent trials suggested that the Crohn’s disease (CD) exclusion diet (CDED) plus partial enteral nutrition (PEN) is a safe and effective strategy in remission induction of paediatric-onset CD. However, real-world evidence regarding the safety and efficacy of the CDED plus PEN approach is still lacking. The present case-series study reported our experience with the outcomes of CDED plus PEN in the paediatric-onset CD at disease onset and after the loss of response to biologics. Methods We conducted a retrospective chart review on children who were treated with CDED plus PEN through the period from July 2019 and December 2020. Clinical and laboratory data were retrieved and compared at baseline, 6, 12, and 24 weeks of treatment. The primary endpoint of the present study was the rate of clinical remission. Results The present study retrieved the data from 15 patients. Of them, nine patients were treatment naïve at the time of initiation of CDED plus PEN (group A) and the remaining patients relapsed on biologics before treatment. All patients in groups A and B exhibited clinical remission in week six, which was sustained until week 12. At the end of the follow-up, the clinical remission rate was 87% and 60% in groups A and B, respectively. No side effects were observed in both groups. In group A, the faecal calprotectin (FC) and albumin improved at week six, week 12, and week 24 (p < 0.05). The erythrocyte sedimentation rate (ESR) improved significantly at week 12 (p = 0.021) and week 24 (p = 0.027). At the same time, the haemoglobin and iron levels showed significant improvement only at week 24. For group B, only FC showed numerical reductions over time that did not reach the level of statistical significance. Conclusion Treatment with CDED plus PEN was well tolerated and achieved an excellent clinical remission rate in treatment-naive patients. However, the benefit of CDED plus PEN was less in patients who initiated the strategy after losing the response to biologics.

Resumen• Propósito: Descripción de dos casos de sarcomas en mujeres que recibieron tamoxifeno después del tratamiento quirúrgico de cáncer de mama.• Material y métodos: Se describen dos casos de dos mujeres de 74 y 53 años que recibieron tratamiento con 20 mg diarios de tamoxifeno después del tratamiento quirúrgico de un cáncer de mama. Cuatro y dos años después de iniciar el tratamiento, desarrollaron un tumor Mülleriano mixto maligno heterólogo (Estadio III) y un sarcoma del estroma endometrial (Estadio I).• Discusión: Los carcinosarcomas y otros sarcomas uterinos son raros, y ocurren en menos del 4% de los tumores uterinos. En la mayoría de los estudios se refieren tasas altas de estos tumores en mujeres postmenopáusicas, con cáncer de mama, tratadas con tamoxifeno, en comparación a las no tratadas, especialmente aquellas expuestas a largos periodos de tratamiento.

During the process of chemotherapy of pediatric patients with cancer, the discomfort proves to be one of the many challenges for the patient, intensified by the ease at which the child becomes upset or annoyed. As a form of distraction during part of the treatment, this poster proposes an application of virtual reality to mask the process, and additionally, allows for association within the cancer patient’s situation

No abstract